News Catalent acquires gene therapy specialist Paragon for $1.2bn Drug delivery technology provider Catalent is to acquire gene therapy company Paragon for $1.2 billion.
News Lundbeck preps for key bexicaserin data around year-end Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
